Table 1 List of key eligibility criteria for studies to be included.
Criteria | Included | Excluded |
|---|---|---|
Population | ▪ Adult (≥18 years) subjects with Follicular lymphoma ▪ Patients had received ≥2 prior lines of therapy. | ▪ Children with follicular lymphoma ▪ Subjects with other types of NHL |
Interventions | ▪ CAR-T treatment | ▪ Dual targeting CAR-T or non-CD19 Targeting CAR-T |
Comparison | ▪ CD20-CD3 Bispecific treatment | ▪ Dual targeting bispecifics or non-CD20-CD3 bispecifics |
Study design | ▪ Prospective interventional clinical trials that determined a therapeutic dose and evaluated the efficacy of CD20×CD3 bispecific monoclonal antibodies or CAR-T-cell therapy for R/R FL will be selected for the meta-analysis ▪ Long-term follow-up studies. | ▪ Preclinical studies ▪ Phase 1 studies at the dose escalation phase ▪ Prognostic studies ▪ Retrospective studies ▪ Case reports ▪ Commentaries and letters (publication type) ▪ Consensus reports ▪ Nonsystematic reviews |
Language | ▪ All languages | ▪ None |
Date | ▪ Jan 2010 to June 2025 | ▪ Studies published prior to Jan 2010 |
